This paper is to comment on an article “The FDA and the Case of Ketek”by Dr. Ross published in New England Journal of Medicine. Dr. Ross B. David, who is a clinical assistant professor discussed the issue of a drug “Ketek”(a ketolide antibiotic) produced by Sanofi-Aventis. The drug was suggested for utilize in society-obtained respiratory tract infections.
In April 2006, in the USA the and FDA recognized twelve cases of severe failure of liver, ensuing 04 deaths, and an extra twenty-three cases of severe liver damage in patients taking the drug. Ketek (Telithromycin) had caused Eighteen demises and at ...